Immix Biopharma (IMMX) Total Current Liabilities (2020 - 2026)

Immix Biopharma has disclosed Total Current Liabilities across 7 years of filings, most recently posting $10.5 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $10.5 million, up 13.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.5 million (up 13.24% YoY), and the FY2025 annual result was $10.1 million, up 16.39% from the prior year.
• Total Current Liabilities came in at $10.5 million for Q1 2026 at Immix Biopharma, up from $10.1 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $10.9 million in Q3 2025 to a low of $365086.0 in Q1 2022.
• The 5-year median for Total Current Liabilities is $3.9 million (2024), against an average of $5.3 million.
• Across the five-year window, Total Current Liabilities surged 530.22% in 2022 and climbed 13.24% in 2026, its largest moves.
• Immix Biopharma's Total Current Liabilities stood at $1.3 million in 2022, then soared by 192.3% to $3.7 million in 2023, then soared by 133.41% to $8.7 million in 2024, then advanced by 16.39% to $10.1 million in 2025, then climbed by 4.24% to $10.5 million in 2026.
• The last three Total Current Liabilities figures came in at $10.5 million (Q1 2026), $10.1 million (Q4 2025), and $10.9 million (Q3 2025), per Business Quant data.